- Home
- GOVX vs LXEH Comparison
GOVX vs LXEH Comparison
Compare GOVX & LXEH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GOVX | LXEH |
|---|---|---|
| Founded | 2001 | 2001 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 3.4M |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GOVX | LXEH |
|---|---|---|
| Price | $0.28 | $1.62 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 814.4K | 311.8K |
| Earning Date | 11-12-2026 | 10-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,489,145.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.27 | $0.16 |
| 52 Week High | $157.50 | $2.50 |
Technical Indicators
Market Signals| Indicator | GOVX | LXEH |
|---|---|---|
| Relative Strength Index (RSI) | 23.04 | 50.41 |
| Support Level | N/A | $1.55 |
| Resistance Level | $0.46 | $1.74 |
| Average True Range (ATR) | 0.04 | 0.24 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 7.65 | 19.63 |
Price Performance
Historical ComparisonAbout GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
About LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is engaged in providing education services, including high school and vocational education services. It offers private basic education at the primary and junior high school levels. The Group has two reportable segments for operations, including high school and vocational education.